Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Intervet International prepares new DGAT1 inhibitors

June 4, 2013

CHMP recommends European approval of once-weekly somatropin

June 3, 2013

European CHMP recommends approval of Lojuxta

June 3, 2013

Depomed to cease investment in Sefelsa following receipt of complete response letter from FDA

June 3, 2013

Novo Nordisk seeks E.U. approval of IDegLira for type 2 diabetes

June 3, 2013

Intervet International prepares new DGAT1 inhibitors

June 3, 2013

Promising in vitro results for a novel gene therapy for mitochondrial diseases

June 3, 2013

Endo Pharmaceuticals receives complete response letter from FDA regarding Aveed NDA

May 31, 2013

BioMarin's applications for Vimizim accepted by both FDA and EMA

May 31, 2013

Array BioPharma patents novel GPR119 receptor agonists

May 31, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...